Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer.

ABSTRACT:

Objective

The tolerability and efficacy of targeted therapy in older adults with cancer has not been adequately studied. Neratinib is a novel HER1, HER2, HER4 tyrosine kinase inhibitor that has recently been granted FDA approval for treatment of breast cancer. The major toxicity of neratinib is diarrhea, which affects up to 90% of patients. This phase II trial evaluates the safety and tolerability of neratinib in adults ≥60.

Methods

Patients aged 60 or older with histologically proven metastatic breast cancer and HER2 amplification (defined by ASCO/CAP guideline) or HER2/HER3 activating mutation were enrolled to receive neratinib at 240 mg daily in 28-day cycles. The association between tolerability, defined as dose reduction and number of completed courses, and log₂

SUBMITTER: Yuan Y 

PROVIDER: S-EPMC8580161 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature